NanoViricides Current Deferred Revenue vs Net Debt Analysis

NNVC Stock

USD 1.10 0.01 0.90%

NanoViricides financial indicator trend analysis is infinitely more than just investigating NanoViricides recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NanoViricides is a good investment. Please check the relationship between NanoViricides Current Deferred Revenue and its Net Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NanoViricides. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.

Current Deferred Revenue vs Net Debt

Current Deferred Revenue vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NanoViricides Current Deferred Revenue account and Net Debt. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between NanoViricides' Current Deferred Revenue and Net Debt is -0.38. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Net Debt in the same time period over historical financial statements of NanoViricides, assuming nothing else is changed. The correlation between historical values of NanoViricides' Current Deferred Revenue and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of NanoViricides are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Current Deferred Revenue i.e., NanoViricides' Current Deferred Revenue and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.38

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from NanoViricides' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NanoViricides current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NanoViricides. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.At present, NanoViricides' Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	723.3K	747.5K	859.7K	772.2K
Interest Income	11.9K	355.8K	409.2K	429.7K

Reconciled Depreciation Interest Income

NanoViricides fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Accounts Payable	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Common Stock	Total Assets	Short Long Term Debt Total	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Non Current Liabilities Total	Other Current Assets	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Preferred Stock Total Equity	Property Plant Equipment	Net Tangible Assets
Other Current Liab		0.06	-0.25	0.05	0.57	0.33	-0.24	-0.1	0.01	0.32	-0.2	0.0	-0.07	0.21	-0.21	-0.06	0.29	-0.21	0.09	0.34	-0.16	-0.21	0.31	0.28	-0.09	-0.44
Total Current Liabilities	0.06		0.11	0.12	0.0	0.21	-0.4	-0.14	0.44	0.23	0.27	0.52	0.38	-0.03	0.16	0.39	-0.03	0.16	0.12	0.02	0.04	0.15	0.29	0.22	0.35	-0.02
Total Stockholder Equity	-0.25	0.11		-0.36	-0.05	-0.37	0.16	0.43	0.44	-0.33	0.91	0.42	0.63	-0.85	0.79	0.66	-0.05	0.79	0.39	0.17	0.4	0.79	0.56	-0.43	0.61	0.89
Retained Earnings	0.05	0.12	-0.36		0.16	0.79	-0.83	-0.96	0.34	0.81	-0.09	0.52	-0.6	-0.07	0.14	-0.59	0.55	0.14	0.52	-0.33	-0.84	0.14	-0.33	0.83	-0.62	-0.21
Accounts Payable	0.57	0.0	-0.05	0.16		0.41	-0.22	-0.14	-0.01	0.4	-0.06	0.08	-0.38	-0.14	0.07	-0.36	0.63	0.07	0.26	0.24	-0.39	0.08	0.42	0.31	-0.39	-0.21
Common Stock Total Equity	0.33	0.21	-0.37	0.79	0.41		-0.75	-0.81	0.06	1.0	-0.23	0.33	-0.44	0.08	-0.08	-0.45	0.46	-0.08	0.3	-0.23	-0.69	-0.08	-0.14	0.99	-0.47	-0.35
Common Stock Shares Outstanding	-0.24	-0.4	0.16	-0.83	-0.22	-0.75		0.88	-0.41	-0.79	-0.07	-0.62	0.22	0.12	-0.17	0.2	-0.45	-0.17	-0.49	0.09	0.74	-0.17	0.08	-0.77	0.27	0.18
Other Stockholder Equity	-0.1	-0.14	0.43	-0.96	-0.14	-0.81	0.88		-0.22	-0.82	0.19	-0.43	0.58	-0.02	-0.01	0.58	-0.51	-0.01	-0.41	0.23	0.89	-0.01	0.37	-0.85	0.63	0.33
Total Liab	0.01	0.44	0.44	0.34	-0.01	0.06	-0.41	-0.22		0.08	0.77	0.93	0.15	-0.64	0.81	0.21	0.43	0.81	0.86	-0.32	-0.07	0.81	0.4	0.04	0.13	0.4
Common Stock	0.32	0.23	-0.33	0.81	0.4	1.0	-0.79	-0.82	0.08		-0.2	0.36	-0.42	0.05	-0.05	-0.43	0.46	-0.05	0.31	-0.19	-0.71	-0.05	-0.13	0.99	-0.46	-0.31
Total Assets	-0.2	0.27	0.91	-0.09	-0.06	-0.23	-0.07	0.19	0.77	-0.2		0.73	0.51	-0.9	0.94	0.56	0.15	0.94	0.67	-0.03	0.25	0.94	0.54	-0.29	0.49	0.84
Short Long Term Debt Total	0.0	0.52	0.42	0.52	0.08	0.33	-0.62	-0.43	0.93	0.36	0.73		0.09	-0.67	0.8	0.15	0.49	0.8	0.89	-0.31	-0.26	0.8	0.33	0.31	0.06	0.38
Property Plant And Equipment Net	-0.07	0.38	0.63	-0.6	-0.38	-0.44	0.22	0.58	0.15	-0.42	0.51	0.09		-0.18	0.19	1.0	-0.63	0.19	-0.16	0.25	0.74	0.18	0.37	-0.45	0.99	0.5
Net Debt	0.21	-0.03	-0.85	-0.07	-0.14	0.08	0.12	-0.02	-0.64	0.05	-0.9	-0.67	-0.18		-0.96	-0.23	-0.41	-0.96	-0.74	0.01	0.05	-0.96	-0.47	0.15	-0.14	-0.79
Cash	-0.21	0.16	0.79	0.14	0.07	-0.08	-0.17	-0.01	0.81	-0.05	0.94	0.8	0.19	-0.96		0.25	0.4	1.0	0.82	-0.13	-0.01	1.0	0.45	-0.14	0.17	0.78
Non Current Assets Total	-0.06	0.39	0.66	-0.59	-0.36	-0.45	0.2	0.58	0.21	-0.43	0.56	0.15	1.0	-0.23	0.25		-0.57	0.25	-0.1	0.24	0.73	0.24	0.43	-0.47	0.98	0.51
Non Currrent Assets Other	0.29	-0.03	-0.05	0.55	0.63	0.46	-0.45	-0.51	0.43	0.46	0.15	0.49	-0.63	-0.41	0.4	-0.57		0.4	0.71	-0.27	-0.67	0.41	0.36	0.39	-0.68	-0.18
Cash And Short Term Investments	-0.21	0.16	0.79	0.14	0.07	-0.08	-0.17	-0.01	0.81	-0.05	0.94	0.8	0.19	-0.96	1.0	0.25	0.4		0.82	-0.13	-0.01	1.0	0.45	-0.14	0.17	0.78
Non Current Liabilities Total	0.09	0.12	0.39	0.52	0.26	0.3	-0.49	-0.41	0.86	0.31	0.67	0.89	-0.16	-0.74	0.82	-0.1	0.71	0.82		-0.35	-0.35	0.83	0.37	0.25	-0.2	0.35
Other Current Assets	0.34	0.02	0.17	-0.33	0.24	-0.23	0.09	0.23	-0.32	-0.19	-0.03	-0.31	0.25	0.01	-0.13	0.24	-0.27	-0.13	-0.35		-0.01	-0.14	0.02	-0.23	0.23	0.1
Property Plant And Equipment Gross	-0.16	0.04	0.4	-0.84	-0.39	-0.69	0.74	0.89	-0.07	-0.71	0.25	-0.26	0.74	0.05	-0.01	0.73	-0.67	-0.01	-0.35	-0.01		-0.02	0.28	-0.71	0.8	0.35
Total Current Assets	-0.21	0.15	0.79	0.14	0.08	-0.08	-0.17	-0.01	0.81	-0.05	0.94	0.8	0.18	-0.96	1.0	0.24	0.41	1.0	0.83	-0.14	-0.02		0.45	-0.14	0.16	0.77
Intangible Assets	0.31	0.29	0.56	-0.33	0.42	-0.14	0.08	0.37	0.4	-0.13	0.54	0.33	0.37	-0.47	0.45	0.43	0.36	0.45	0.37	0.02	0.28	0.45		-0.26	0.34	0.19
Preferred Stock Total Equity	0.28	0.22	-0.43	0.83	0.31	0.99	-0.77	-0.85	0.04	0.99	-0.29	0.31	-0.45	0.15	-0.14	-0.47	0.39	-0.14	0.25	-0.23	-0.71	-0.14	-0.26		-0.48	-0.37
Property Plant Equipment	-0.09	0.35	0.61	-0.62	-0.39	-0.47	0.27	0.63	0.13	-0.46	0.49	0.06	0.99	-0.14	0.17	0.98	-0.68	0.17	-0.2	0.23	0.8	0.16	0.34	-0.48		0.52
Net Tangible Assets	-0.44	-0.02	0.89	-0.21	-0.21	-0.35	0.18	0.33	0.4	-0.31	0.84	0.38	0.5	-0.79	0.78	0.51	-0.18	0.78	0.35	0.1	0.35	0.77	0.19	-0.37	0.52

Click cells to compare fundamentals

NanoViricides Account Relationship Matchups

NanoViricides fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	630.8K	55.8K	260.1K	377.2K	433.8K	618.7K
Total Current Liabilities	2.2M	351.1K	412.8K	534.3K	614.4K	583.7K
Total Stockholder Equity	21.8M	29.9M	23.1M	14.9M	17.1M	15.3M
Retained Earnings	(105.6M)	(114.4M)	(122.5M)	(131.1M)	(118.0M)	(112.1M)
Accounts Payable	380.7K	200.0K	58.0K	157.1K	141.4K	274.0K
Common Stock Total Equity	69.2K	76.9K	9.1K	11.5K	10.4K	9.8K
Common Stock Shares Outstanding	5.6M	10.9M	11.5M	11.6M	13.4M	14.0M
Other Stockholder Equity	127.3M	144.3M	145.6M	145.9M	167.8M	176.2M
Total Liab	2.2M	351.1K	412.8K	2.0M	2.3M	4.3M
Common Stock	9.1K	11.5K	11.6K	116.0	104.4	99.18
Total Assets	23.9M	30.3M	23.5M	16.9M	19.4M	20.7M
Property Plant And Equipment Net	9.5M	9.1M	8.7M	8.1M	9.3M	6.2M
Net Debt	(12.6M)	(20.4M)	(14.0M)	(8.1M)	(7.3M)	(7.7M)
Cash	13.7M	20.5M	14.1M	8.1M	9.4M	13.7M
Non Current Assets Total	9.9M	9.4M	9.1M	8.5M	9.7M	6.7M
Non Currrent Assets Other	25.9K	3.5K	42.4K	14.4K	12.9K	12.3K
Cash And Short Term Investments	13.7M	20.5M	14.1M	8.1M	9.4M	13.7M
Liabilities And Stockholders Equity	23.9M	30.3M	23.5M	16.9M	19.4M	20.7M
Non Current Liabilities Total	1.5M	295.3K	152.7K	1.5M	1.4M	1.3M
Other Current Assets	277.1B	307.1B	350.0K	295.5K	339.8K	322.8K
Property Plant And Equipment Gross	9.5M	9.1M	14.7M	14.8M	17.0M	17.9M
Total Current Assets	14.0M	20.8M	14.4M	8.4M	9.7M	14.1M
Intangible Assets	358.4K	350.1K	341.8K	333.6K	383.6K	357.5K
Property Plant Equipment	9.5M	9.1M	8.7M	8.1M	9.3M	8.4M
Net Tangible Assets	21.4M	29.6M	22.7M	14.5M	16.7M	22.0M
Net Invested Capital	22.9M	30.0M	23.2M	14.9M	17.1M	22.5M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether NanoViricides offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NanoViricides' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nanoviricides Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nanoviricides Stock:

How To Invest In NanoViricides

Details

Is NanoViricides Stock a good investment?

Details

What is NanoViricides' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NanoViricides. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.

You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Complementary Tools for NanoViricides Stock analysis

When running NanoViricides' price analysis, check to measure NanoViricides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NanoViricides is operating at the current time. Most of NanoViricides' value examination focuses on studying past and present price action to predict the probability of NanoViricides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NanoViricides' price. Additionally, you may evaluate how the addition of NanoViricides to your portfolios can decrease your overall portfolio volatility.

	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators

Is NanoViricides' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NanoViricides. If investors know NanoViricides will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NanoViricides listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.80)

Return On Assets

(0.36)

Return On Equity

(0.58)

The market value of NanoViricides is measured differently than its book value, which is the value of NanoViricides that is recorded on the company's balance sheet. Investors also form their own opinion of NanoViricides' value that differs from its market value or its book value, called intrinsic value, which is NanoViricides' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NanoViricides' market value can be influenced by many factors that don't directly affect NanoViricides' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NanoViricides' value and its price as these two are different measures arrived at by different means. Investors typically determine if NanoViricides is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NanoViricides' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NanoViricides Current Deferred Revenue vs Net Debt Analysis

Current Deferred Revenue vs Net Debt

Current Deferred Revenue vs Net Debt Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Net Debt

NanoViricides fundamental ratios Correlations

NanoViricides Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NanoViricides fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for NanoViricides Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Preferred Stock Total Equity	+ 0.99	Common Stock Total Equity

Total Current Assets	- 0.96	Net Debt
Cash And Short Term Investments	- 0.96	Net Debt
Cash	- 0.96	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Net Debt	- 0.9	Total Assets
Preferred Stock Total Equity	- 0.85	Other Stockholder Equity